Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Registration Number
- NCT04453397
- Lead Sponsor
- TeneoOne Inc.
- Brief Summary
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Adequate bone marrow function
- eGFR ≥ 30 mL/min
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- Serum calcium (corrected for albumin) at or below the ULN range
Exclusion Criteria
- Candidate for treatment regimens known to provide clinical benefit in MM
- Active infection requiring parenteral anti-infective treatment
- Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Wake Forest
🇺🇸Winston-Salem, North Carolina, United States